

1           **Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest**  
2                           **computed tomography for the diagnosis of COVID-19**

3  
4           Kazuo Imai <sup>a-c\*</sup>, Sakiko Tabata <sup>a</sup>, Mayu Ikeda <sup>a</sup>, Sakiko Noguchi <sup>d</sup>, Yutaro Kitagawa <sup>d</sup>  
5           Masaru Matsuoka <sup>d</sup>, Kazuyasu Miyoshi <sup>a</sup>, Norihito Tarumoto <sup>b, c</sup>, Jun Sakai <sup>b, c</sup>, Toshimitsu Ito <sup>a</sup>,  
6                           Shigefumi Maesaki <sup>b, c</sup>, Kaku Tamura <sup>a</sup>, Takuya Maeda <sup>c, d</sup>

7  
8           a; COVID-19 Task Force, Self-Defense Forces Central Hospital, Tokyo, Japan

9           b; Department of Infectious Disease and Infection Control, Saitama Medical University, Saitama,  
10          Japan

11          c; Center for Clinical Infectious Diseases and Research, Saitama Medical University, Saitama, Japan

12          d; Department of Clinical Laboratory, Saitama Medical University, Saitama, Japan

13  
14          \* **Corresponding author**

15          Kazuo Imai, M.D.

16          Self-Defense Forces Central Hospital, 24-2-1 Ikejiri, Setagaya-ku, Tokyo, 154-0001, Japan

17          Department of Infectious Disease and Infection Control, Saitama Medical University, 38 Morohongo,  
18          Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan

19          E-mail: [k\\_imai@saitama-med.ac.jp](mailto:k_imai@saitama-med.ac.jp)

20          Tel: +81-3-3411-0151 or +81-3-49-276-1111

21  
22          **Running title:** IgM/IgG antibody assay and chest CT scan for COVID-19

23 **Abstract**

24 **Background:** We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG  
25 antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest  
26 computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19).

27 **Methods:** We examined 139 serum specimens collected from 112 patients with COVID-19 and 48  
28 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for  
29 SARS-CoV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG  
30 Antibody Test. Chest CT was performed in COVID-19 patients on admission.

31 **Findings:** Of the 139 COVID-19 serum specimens, IgM was detected in 27.8%, 48.0%, and 95.8% of  
32 the specimens collected within 1 week, 1–2 weeks, and >2 weeks after symptom onset and IgG was  
33 detected in 3.3%, 8.0%, and 62.5%, respectively. Among the 48 non-COVID-19 serum specimens, 1  
34 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were  
35 asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were  
36 positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in  
37 combination with the IC assay was 57.9 % (22/38) and 68.4% (26/38) for the asymptomatic patients  
38 and 74.3% (55/74) and 82.4% (61/74) for the symptomatic patients, respectively.

39 **Conclusion:** The IC assay had low sensitivity during the early phase of infection, and thus IC assay  
40 alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available,  
41 the combination of chest CT and IC assay may be useful for diagnosing COVID-19.

## 42 **Introduction**

43           The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) epidemic, which causes  
44 the novel coronavirus disease 2019 (COVID-19), was first reported in December 2019 in Wuhan,  
45 China (1), and it has since been declared a pandemic by the World Health Organization. The ongoing  
46 outbreak is a global threat to human health. Quantitative reverse-transcription polymerase chain  
47 reaction (RT-qPCR) analysis for SARS-CoV2 is considered the gold standard for diagnosing  
48 COVID-19. RT-qPCR has been used to analyze specimens from the upper and lower respiratory  
49 tracts for clinical diagnosis during outbreaks of other diseases, but it has not been performed widely  
50 in the clinical setting because it requires special equipment, a time-consuming protocol, and highly  
51 skilled laboratory technicians. In addition, because RT-qPCR requires samples from the upper and  
52 lower respiratory tracts, the process of collecting samples and extracting RNA increases the risk of  
53 exposure to viral droplets. Therefore, an alternative diagnostic test to RT-qPCR is desirable for the  
54 clinical management of COVID-19.

55           In studies conducted in China, chest computed tomography (CT) scans were widely utilized as  
56 a diagnostic tool for COVID-19 (2-4). Lung involvement can be detected in patients with COVID-19  
57 on a CT scan in advance of the symptoms typical for pneumonia (5) and a positive result on  
58 RT-qPCR (6, 7). The common radiological characteristics of COVID-19 pneumonia on chest CT  
59 have a diagnostic sensitivity of 73%–93% and a specificity of 24%–100% in distinguishing  
60 COVID-19 from other forms of viral pneumonia (2, 8). An immunochromatographic (IC) assay for  
61 IgM and IgG antibodies against the virus is widely accepted as a point-of-care test because it is an  
62 easy-to-perform, rapid, and high-throughput method for diagnosing viral infections. Recently, several  
63 commercial IC assays that detect IgM/IgG antibodies against SARS-CoV2 have become available  
64 for use in the clinical setting. However, their clinical usefulness has yet to be thoroughly evaluated.  
65 Here, we describe the clinical performance of an IC assay in comparison with that of chest CT.

66

## 67 **Materials and Methods**

### 68 *Patients with COVID-19 and their clinical specimens*

69 Patients with laboratory-confirmed COVID-19 who were referred to the Self-Defense  
70 Forces Central Hospital and Saitama Medical University Hospital in Japan from February 11 to  
71 March 31, 2020 were enrolled in this study. All patients were examined by RT-qPCR for  
72 SARS-CoV2 using pharyngeal and nasopharyngeal swabs collected at public health institutes or  
73 hospitals in accordance with the nationally recommended method in Japan (9). Chest CT was  
74 performed on the day of admission. Serum specimens were collected on the day of admission and  
75 during hospitalization. Clinical information was collected from the medical records. The CT findings  
76 were evaluated by a radiologist to determine the specific features caused by COVID-19 (2).

77

### 78 *Negative samples from patients with non-COVID-19*

79 To evaluate the analytical specificity of the IC assay, we used serum samples collected from  
80 patients at Saitama Medical University Hospital, Japan, from April to October 2019, before  
81 SARS-CoV2 was first reported in China. Clinical information was collected from the medical  
82 records, and all serum samples were stored at  $-80^{\circ}\text{C}$  before use in the IC assay.

83

### 84 *Definition*

85 Asymptomatic cases were defined as patients with no history of clinical signs or symptoms.  
86 Symptomatic cases were defined as patients showing the clinical symptoms of COVID-19: fever,  
87 cough, nasal discharge, diarrhea, malaise, dyspnea, tachypnea, peripheral capillary oxygen saturation  
88  $<93\%$ , and need for oxygen therapy. The day of onset was defined as the first day of symptoms  
89 caused by COVID-19 in the symptomatic patients or the day of the first positive RT-qPCR result for  
90 upper respiratory specimens in the asymptomatic patients.

91

92 *Detection of IgM and IgG antibodies for SARS-CoV2*

93 IgM/IgG antibody tests for SARS-CoV2 were performed using the One Step Novel  
94 Coronavirus (COVID-19) IgM/IgG Antibody Test (Artron, Burnaby, Canada) according to the  
95 manufacturer's instructions. In brief, 10  $\mu$ L serum was added to the sample port of the IC assay and  
96 was incubated for 20–30 s. Subsequently, 2 drops of sample buffer were added to the same sample  
97 port, and the results were interpreted after a 15–20 min incubation. The presence of only the control  
98 line indicates a negative result; the presence of both the control line and the IgM or IgG antibody line  
99 indicates a positive result for IgM or IgG antibody, respectively.

100

101 *Ethical statement*

102 The study design and protocol were reviewed and approved by the Institutional Review  
103 Board of the Japan Self-Defense Forces Central Hospital (Approval No. 01-011) and Saitama  
104 Medical University Hospital (Approval Nos. 19136 and 20001).

105

106 **Results**

107 *Sensitivity and specificity of the IC assay for COVID-19*

108 IgM and IgG antibodies for SARS-CoV2 could be detected by the IC assay. In total, 139  
109 serum samples were collected from 112 patients with laboratory-confirmed COVID-19 and were  
110 used as positive controls for the IC assay in this study. The medium period from onset to serum  
111 collection was 6 days (interquartile range [IQR], 3–13 days). The results of the IC assay for serum  
112 specimens are shown in Table 1. The serum samples were subdivided into three groups according to  
113 sample collection times: within 1 week (n = 90), 1–2 weeks (n = 25), and >2 weeks after onset (n =  
114 24). IgM antibody was detected in 60 (43.2%) of the 139 serum samples collected and IgG antibody  
115 was detected in 20 (14.4%) specimens. All IgG antibody-positive samples were also positive for IgM  
116 antibody in the IC assay. Thus, the sensitivity of the IC assay was calculated to be 43.2% for all

117 serum specimens. IgM antibody was detected in 27.8% (25/90) of specimens collected within 1 week  
118 of onset, 48.0% (12/25) collected within 1–2 weeks, and 95.8% (23/24) collected >2 weeks after  
119 onset. The corresponding detection rates for IgG antibody were 3.3% (3/90 specimens), 8.0% (2/25  
120 specimens), and 62.5% (15/25 specimens).

121 In IC assays of the 48 non-COVID-19 serum specimens collected before the emergence of  
122 SARS-CoV2 infection, 1 specimen from a patient with Sjogren’s syndrome and rheumatoid arthritis  
123 showed a false-positive result for IgM antibody. Thus, the specificity of the IC assay was calculated  
124 to be 98.0%.

125

#### 126 *IC assay and chest CT for patients with asymptomatic and symptomatic COVID-19*

127 Clinical background of the 112 patients hospitalized due to COVID-19 in this study are  
128 shown in Table 2. Thirty-eight (33.9%) patients who had no COVID-19 symptoms were classified as  
129 asymptomatic and the remaining 74 (66.1%) were classified as symptomatic. Briefly, patients were  
130 aged 20–93 years (median, 67 years; IQR, 45–74 years), and 64 (57.1%) were men. All  
131 asymptomatic patients were diagnosed with COVID-19 by RT-qPCR while under quarantine in  
132 Japan. Of the 38 asymptomatic patients, median time from the first RT-qPCR–positive day to  
133 admission was 5 days (IQR, 3–6 days). Of the 74 symptomatic patients, median time from onset to  
134 admission was 5 days (IQR, 2–7 days).

135 Table 3 shows the results of the IC assay and chest CT for the patients on admission. When  
136 using serum samples taken from the 38 asymptomatic patients, IgM antibody was detected in 15  
137 (39.5%) patients on admission, and none of the patients were positive for IgG antibody. Chest CT  
138 showed abnormal lung findings consistent with the radiographic features of COVID-19 in 22  
139 (57.9%) asymptomatic patients on admission. When the combination of IC assay and chest CT  
140 findings was used for diagnosis in the asymptomatic patients, the sensitivity was 68.4%.

141 Of the 74 symptomatic patients, IgM antibody was detected in 22 (29.7%) patients and IgG

142 antibody in 7 (9.5%) patients. All IgG antibody-positive patients were also positive for IgM antibody.  
143 The sensitivity of the IC assay was 17.0% (9/53) within 1 week, 33.3% (4/12) within 1–2 weeks, and  
144 100.0% (9/9) within >2 weeks after onset. Of the 74 symptomatic patients, chest CT detected the  
145 radiographical patterns of COVID-19 in 55 (74.3%) patients on admission. The corresponding  
146 sensitivity of chest CT was 73.3% (39/53 patients), 66.7% (8/12), and 88.9% (8/9). When the  
147 combination of IC assay and chest CT was used for diagnosis in symptomatic COVID-19 patients,  
148 the corresponding sensitivity was 81.1% (43/53 patients), 75.0% (9/12), and 100% (9/9).

149

## 150 **Discussion**

151 Here, we presented the analytical results of a commercial IC assay and findings of chest CT  
152 scans for patients with COVID-19. Although the IC assay showed high sensitivity for samples  
153 collected >2 weeks after symptom onset, it was less sensitive for patients who developed  
154 symptomatic COVID-19 within 1 week. Chest CT showed higher sensitivity than the IC assay for the  
155 diagnosis of COVID-19, but it did not show the specific radiological features of COVID-19 in 18.3%  
156 of symptomatic patients. Nevertheless, the combination of IC assay and chest CT slightly increased  
157 the diagnostic sensitivity for COVID-19.

158 Based on previous enzyme-linked immunosorbent assay (ELISA) results for IgM and IgG  
159 antibodies, only 38.3% of patients were positive for IgM antibody within the first week after onset.  
160 The detection of IgM and IgG antibodies increased rapidly from day 15 after onset (IgM = 94.3%  
161 and IgG = 79.8%) (10). Our IC assay results support these previous findings that seroconversion  
162 mainly occurred >2 weeks after onset (10). The clinical usefulness of serological tests for COVID-19  
163 remains controversial due to the time lag between the onset of symptoms and the appearance of IgM  
164 and IgG antibodies in serum. In China and the United States, the sensitivity and specificity of  
165 serological tests for samples initially collected from hospitalized patients were 38.3%–85.4% and  
166 100% (10-12) for ELISA and 18.4%–88.7% and 90.6%–91.7% for IC assay (13, 14), respectively.

167 This contradiction probably reflects differences in the timing of sampling because the clinical setting  
168 varies in each country. In the clinical setting, patients are usually diagnosed with COVID-19 within 2  
169 weeks because they develop dyspnea and pneumonia at a median of 8 days (IQR, 5.0–13.0 days)  
170 after symptom onset (1). In this study, the median time from onset to hospitalization was 5 days (IQR,  
171 2–7 days), which is shorter than in previous studies (median 7–15 days) (10-14). Additionally, only  
172 29.7% of patients were diagnosed using IC assay alone, supporting the Cassaniti et al.'s conclusion  
173 that the sensitivity of IC assays remains insufficient for their use as a clinical diagnostic tool (14).  
174 Therefore, unfortunately, the IC assay alone cannot replace RT-qPCR as an acute diagnostic protocol  
175 for COVID-19, at least in the clinical setting in Japan. However, the IC assay can be used for  
176 epidemiological studies of the seroprevalence of IgM and IgG antibodies against SARS-CoV2.

177 Previous studies have shown that the sensitivity of CT among symptomatic patients was  
178 high (73%–97%), although specificity differed widely (24%–100%) (7, 8, 15, 16). The clinical  
179 performance of CT may vary according to differences in patient populations, disease severity, and  
180 accessibility to chest CT scans in each country. In the present study, chest CT showed higher  
181 sensitivity than the IC assay, but sensitivity was only 73.3% among the symptomatic patients who  
182 tested positive for SARS-CoV2 according to RT-qPCR. Bernheim et al. reported that the sensitivity  
183 of chest CT was low (44%) in the acute phase (0–2 days after onset) but high (91%) in the  
184 intermediate phase (3–5 days) (16). The low sensitivity of chest CT may reflect the short period of  
185 time between symptom onset to hospitalization in the symptomatic patients examined in this study.  
186 The diagnostic sensitivity was improved by combining the IC assay and chest CT (81.3%). In the  
187 present study, we did not evaluate the specificity of chest CT, but taking the high specificity of the IC  
188 assay into consideration, combining the IC assay and chest CT was considered to improve the  
189 diagnostic specificity as well. When RT-qPCR is not available or practical, the combination may be  
190 useful for diagnosing COVID-19.



191 The identification of asymptomatic patients with COVID-19 is important to prevent  
192 nosocomial infection. The average incubation period of COVID-19 is 5.2 days (17) but ranges from  
193 0 to 24 days (15). It has also been reported that patients hospitalized with other diseases who did not  
194 show respiratory symptoms developed symptomatic COVID-19 and they spread SARS-CoV2 to  
195 other patients and medical workers (18). Also, the transmission of SARS-CoV2 from patients  
196 without respiratory symptoms has been reported in several countries (19-21). In the present study,  
197 chest CT showed higher sensitivity than the IC assay (57.9% vs. 39.5%, respectively), but it is not  
198 practical to perform chest CT for all hospitalized patients because of radiation exposure risk and  
199 limited medical resources (22). Although the IC assay alone may not be useful as a screening test for  
200 asymptomatic COVID-19 due to its low sensitivity, it may contribute to the prevention of  
201 nosocomial infection.

202 A major limitation of this study was the low number of patients. In addition, only one  
203 commercial IC kit was evaluated. The commercial IC assay verified to have the best performance in  
204 the clinical setting should be chosen for further studies. Multicenter, multi-national, prospective  
205 studies are warranted to determine the usefulness of IC assays and chest CT for diagnosing  
206 COVID-19.

207

## 208 **Conclusion**

209 The sensitivity of the IC assay was low during the early phase in asymptomatic and  
210 symptomatic patients. Therefore, IC assay alone is not recommended for initial diagnostic testing for  
211 COVID-19. When RT-qPCR cannot be used, the combination of chest CT and IC assay may be  
212 useful for diagnosing COVID-19.

213

## 214 **Declaration of interests**

215 The authors declare that they have no conflicts of interests.

216

217 **Role of the funding source**

218           This research did not receive any specific grant from funding agencies in the public,  
219 commercial, or nonprofit sectors.

220

221 **Acknowledgments**

222           We thank everyone involved in the COVID-19 Task Force at the Self-Defense Forces  
223 Central Hospital in Japan and members who were assembled from other institutes of the Japan  
224 Self-Defense Forces.

225 **References**

- 226 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T,  
227 Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G,  
228 Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019  
229 novel coronavirus in Wuhan, China. *The Lancet* 395:497-506.
- 230 2. Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, Pan I, Shi L-B, Wang D-C, Mei J,  
231 Jiang X-L, Zeng Q-H, Egglin TK, Hu P-F, Agarwal S, Xie F, Li S, Healey T, Atalay MK,  
232 Liao W-H. 2020. Performance of radiologists in differentiating COVID-19 from viral  
233 pneumonia on chest CT. *Radiology*. doi:10.1148/radiol.2020200823
- 234 3. Huang P, Liu T, Huang L, Liu H, Lei M, Xu W, Hu X, Chen J, Liu B. 2020. Use of Chest CT  
235 in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High  
236 Clinical Suspicion. *Radiology*. doi:10.1148/radiol.2020200330:200330.
- 237 4. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, Zheng D, Wang J, Hesketh RL, Yang L, Zheng C.  
238 2020. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel  
239 Coronavirus (COVID-19) Pneumonia. *Radiology*. doi:10.1148/radiol.2020200370:200370.
- 240 5. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. 2020. Radiological findings  
241 from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *The*  
242 *Lancet Infectious Diseases*. doi:10.1016/S1473-3099(20)30086-4.
- 243 6. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. 2020. Sensitivity of Chest CT for

- 244 COVID-19: Comparison to RT-PCR. *Radiology*. doi:10.1148/radiol.2020200432.
- 245 7. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. 2020. Correlation of  
246 Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report  
247 of 1014 Cases. *Radiology*. doi:10.1148/radiol.2020200642:200642.
- 248 8. Caruso D, Zerunian M, Polici M, Pucciarelli F, Polidori T, Rucci C, Guido G, Bracci B,  
249 Dominicis Cd, Laghi PA. 2020. Chest CT Features of COVID-19 in Rome, Italy. *Radiology*.  
250 doi:10.1148/radiol.2020201237.
- 251 9. Nao N, Shirato K, Katano H, Matsuyama S, Takeda M. 2020. Detection of second case of  
252 2019-nCoV infection in Japan. 2020. National Institute of Infectious Diseases.  
253 [https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2\\_erratum.pdf](https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2_erratum.pdf) [Latest  
254 accessed 26/Mar/2020]
- 255 10. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S, Hong C,  
256 Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang J, Xia N,  
257 Zhang Z. 2020. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease  
258 2019. *Clin Infect Dis*. doi:10.1093/cid/ciaa344.
- 259 11. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z,  
260 Zheng S. 2020. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting  
261 antibodies against SARS-CoV-2. *Journal of Clinical Microbiology*.  
262 doi:10.1128/jcm.00461-20:JCM.00461-20.

- 263 12. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang  
264 L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J.  
265 2020. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease  
266 (COVID-19). *Clin Infect Dis*. doi:10.1093/cid/ciaa310.
- 267 13. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, Sun R, Wang Y, Hu B, Chen W, Zhang Y, Wang J,  
268 Huang B, Lin Y, Yang J, Cai W, Wang X, Cheng J, Chen Z, Sun K, Pan W, Zhan Z, Chen L,  
269 Ye F. 2020. Development and Clinical Application of A Rapid IgM-IgG Combined Antibody  
270 Test for SARS-CoV-2 Infection Diagnosis. *J Med Virol*. doi:10.1002/jmv.25727.
- 271 14. Cassaniti I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, Bruno R, Mojoli F,  
272 Baldanti F, Force MotSMPC-T. Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is  
273 inadequate for diagnosis of COVID-19 in acute patients referring to emergency room  
274 department. *Journal of Medical Virology*. doi:10.1002/jmv.25800.
- 275 15. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-l, Hui DSC, Du B,  
276 Li L-j, Zeng G, Yuen K-Y, Chen R-c, Tang C-l, Wang T, Chen P-y, Xiang J, Li S-y, Wang J-l,  
277 Liang Z-j, Peng Y-x, Wei L, Liu Y, Hu Y-h, Peng P, Wang J-m, Liu J-y, Chen Z, Li G, Zheng  
278 Z-j, Qiu S-q, Luo J, Ye C-j, Zhu S-y, Zhong N-s. 2020. Clinical Characteristics of  
279 Coronavirus Disease 2019 in China. *New England Journal of Medicine*.  
280 doi:10.1056/NEJMoa2002032.
- 281 16. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, Li

- 282 S, Shan H, Jacobi A, Chung M. 2020. Chest CT Findings in Coronavirus Disease-19  
283 (COVID-19): Relationship to Duration of Infection. *Radiology*.  
284 doi:10.1148/radiol.2020200463:200463.
- 285 17. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY,  
286 Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L,  
287 Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng  
288 Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM,  
289 Feng Z. 2020. Early Transmission Dynamics in Wuhan, China, of Novel  
290 Coronavirus–Infected Pneumonia. *New England Journal of Medicine* 382:1199-1207.
- 291 18. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y,  
292 Li Y, Wang X, Peng Z. 2020. Clinical Characteristics of 138 Hospitalized Patients With 2019  
293 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*.  
294 doi:10.1001/jama.2020.1585.
- 295 19. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V,  
296 Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirgmaier K, Zange S, Wolfel  
297 R, Hoelscher M. 2020. Transmission of 2019-nCoV Infection from an Asymptomatic Contact  
298 in Germany. *N Engl J Med*. doi:10.1056/NEJMc2001468.
- 299 20. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, Wang M. 2020. Presumed Asymptomatic  
300 Carrier Transmission of COVID-19. *Jama* doi:10.1001/JAMA.2020.2565.

- 301 21. Yu P, Zhu J, Zhang Z, Han Y, Huang L. 2020. A familial cluster of infection associated with  
302 the 2019 novel coronavirus indicating potential person-to-person transmission during the  
303 incubation period. *J Infect Dis.* doi:10.1093/infdis/jiaa077.
- 304 22. Nakajima K, Kato H, Yamashiro T, Izumi T, Takeuchi I, Nakajima H, Utsunomiya D. 2020.  
305 COVID-19 pneumonia: infection control protocol inside computed tomography suites.  
306 *Japanese Journal of Radiology.* doi:10.1007/s11604-020-00948-y.  
307  
308

309

310 Table 1: IC assay for IgM and IgG antibodies using COVID-19–positive serum specimens

	Total N = 139	Time from symptom onset to specimen collection		
		<1 week n = 90	1–2 weeks n = 25	>2 weeks n = 24
IgM	60 (43.2%)	25 (27.8%)	12 (48.0%)	23 (95.8%)
IgG	20 (14.4%)	3 (3.3%)	2 (8.0%)	15 (62.5%)
IgM + IgG	60 (43.2%)	25 (27.8%)	12 (48.0%)	23 (95.8%)

311 Data are n (%).

312

313



314 Table 2: Clinical characteristics of patients with COVID-19 on admission

Characteristics	Total N = 112	Asymptomatic n = 38	Symptomatic n = 74
Age (years)	67 (45–74)	68 (61.5–73.75)	65 (40–74.5)
Sex (male)	64 (57.1%)	16 (42.1%)	48 (64.8%)
Time from onset to admission (days)	5 (2–7)	NA	5 (2–7)
Time from first RT-qPCR–positive day to admission (days)	3 (2–6)	5 (3–6)	3 (1.75–5)

315 Data are n (%), or median (IQR), unless otherwise specified. NA, not applicable.

316

317 Table 3: IC assay and chest CT findings for patients with COVID-19 on admission

	Asymptomatic			Symptomatic			
	Total n = 38	Time from first RT-qPCR–positive day to admission		Total n = 74	Time from onset to admission		
		<1 week n = 35	1–2 weeks n = 3		<1 week n = 53	1–2 weeks n = 12	>2 weeks n = 9
IgM	15 (39.5%)	14 (40.0%)	1 (33.3%)	22 (29.7%)	9 (17.0%)	4 (33.3%)	9 (100.0%)
IgG	0 (0%)	0 (0%)	0 (0%)	7 (9.5%)	2 (3.8%)	1 (8.3%)	4 (44.4%)
IgM + IgG	15 (39.5%)	14 (40.0%)	1 (33.3%)	22 (29.7%)	9 (17.0%)	4 (33.3%)	9 (100.0%)
CT scan	22 (57.9%)	19 (54.2%)	3 (100.0%)	55 (74.3%)	39 (73.6%)	8 (66.7%)	8 (88.9%)
IgM + IgG + CT scan	26 (68.4%)	23 (65.7%)	3 (100.0%)	61 (82.4%)	43 (81.1%)	9 (75.0%)	9 (100.0%)

318 Data are n (%).

319